beacon-discovery

Beacon Discovery is a GPCR-focused small molecule drug discovery company comprised of a team of dedicated scientists who have worked together in GPCR drug discovery for more than 15 years. The Beacon team has delivered more than 20 drug candidates into clinical development, and of these two are now approved products, and six remain in clinical testing. As a GPCR drug discovery incubator, Beacon has leveraged its research portfolio and expertise to secure partnerships with both small biotech start-ups and large pharma partners. These partnerships represent validation of our approach. We believe that no other company can boast the experience or expertise of Beacon Discovery in the field of GPCR research for drug discovery. We use proprietary know-how and lessons learned from our years of experience with this target class to discover novel chemical matter for intractable GPCRs that have, to date, eluded traditional HTS screening approaches. Our team retains expertise in all aspects of GPCR drug discovery including: medicinal and computational chemistry, high throughput screening, and in vitro and in vivo pharmacology.